Clinical trial
A Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or…
NCT00497497 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00497497 |
|---|---|
| Title | A Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer (APM4187g) |
| Official title | A Phase Ib, Dose-Escalation Study of the Safety and Pharmacokinetics of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | bevacizumab, cetuximab, FOLFIRI regimen, irinotecan, PRO95780 |
| Enrollment | 20 |
| Start date | Oct 1, 2007 |
| Primary completion | Sep 1, 2010 |
| Completion | Sep 1, 2010 |
| First posted | Jul 6, 2007 |
| Last update posted | May 19, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: